血清NMDA受体抗体与首发精神病抗精神病药治疗反应的关系
该研究检测了387例首发精神病患者(精神病病程<2年、极少或未用过抗精神病药)的血清NMDAR IgG抗体,并予氨磺必利初始治疗4周。基线15例血清阳性、372例阴性;阳性者精神病病程更短(中位1.5 vs 4.0个月,p=.031),但4周后PANSS评分改善及不良反应频率组间无差异。结论提示,仅NMDAR抗体血清阳性不足以作为改用免疫治疗替代抗精神病药的指征。
要点
- 首发精神病中NMDAR抗体血清阳性率低,阳性者病程更短。
- 血清阳性与阴性者4周氨磺必利治疗的PANSS改善无差异。
- 仅血清NMDAR抗体阳性不应作为跳过抗精神病药改用免疫治疗的依据。
核心结论
- 在首发精神病中,仅NMDAR抗体血清阳性不构成使用免疫治疗替代抗精神病药物的指征。
- 需进一步研究血清阳性患者中合并脑脊液炎症改变或其他辅助检查提示免疫治疗可能获益的比例。
研究设计与样本
- 研究纳入387例首发精神病患者(精神病病程<2年、极少或未使用抗精神病药),为OPTiMiSE试验(NCT01248195)中初始接受氨磺必利治疗者。
- 采用活细胞法检测血清NMDAR IgG抗体,并在基线和氨磺必利治疗4周后以PANSS和CGI评估症状严重度。
主要发现
- 基线时15例血清阳性、372例血清阴性;两组症状谱和人口学特征相似。
- 血清阳性组精神病病程中位1.5个月,短于血清阴性组的4.0个月(p = .031)。
关键数值与推荐
- 血清NMDAR抗体阳性:15/387例;阴性:372/387例。
- 精神病病程中位:血清阳性1.5个月 vs 血清阴性4.0个月,p = .031。
临床怎么用
- 对首发精神病患者,不应仅凭血清NMDAR抗体阳性就放弃抗精神病药物而改用免疫治疗。
- 血清NMDAR抗体阳性且病程短者,可结合脑脊液炎症改变等辅助检查综合评估免疫治疗的必要性。
局限性
- 原文未报告血清阳性患者中脑脊液炎症改变或其他辅助检查结果的比例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: When psychosis develops in NMDA receptor (NMDAR) antibody encephalitis, it usually has an acute or subacute onset, and antipsychotic treatment may be ineffective and associated with adverse effects. Serum NMDAR antibodies have been reported in a minority of patients with first-episode psychosis (FEP), but their role in psychosis onset and response to antipsychotic treatment is unclear. METHODS: Sera from 387 patients with FEP (duration of psychosis <2 years, minimally or never treated with antipsychotics) undergoing initial treatment with amisulpride as part of the OPTiMiSE (Optimization of Treatment and Management of Schizophrenia in Europe) trial (ClinicalTrials.gov number NCT01248195) were tested for NMDAR IgG antibodies using a live cell-based assay. Symptom severity was assessed using the Positive and Negative Syndrome Scale and the Clinical Global Impressions Scale at baseline and again after 4 weeks of treatment with amisulpride. RESULTS: At baseline, 15 patients were seropositive for NMDAR antibodies and 372 were seronegative. The seropositive patients had similar symptom profiles and demographic features to seronegative patients but a shorter duration of psychosis (median 1.5 vs. 4.0 months; p = .031). Eleven seropositive and 284 seronegative patients completed 4 weeks of amisulpride treatment: after treatment, there was no between-groups difference in improvement in Positive and Negative Syndrome Scale scores or in the frequency of adverse medication effects. CONCLUSIONS: These data suggest that in FEP, NMDAR antibody seropositivity alone is not an indication for using immunotherapy instead of antipsychotic medications. Further studies are required to establish what proportion of patients with FEP who are NMDAR antibody seropositive have coexisting cerebrospinal fluid inflammatory changes or other paraclinical evidence suggestive of a likely benefit from immunotherapy.
引用
- Pollak TA, Vincent A, Iyegbe C, et al. Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis. Biol Psychiatry. 2020. PMID: 33536130. doi:10.1016/j.biopsych.2020.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。